Urgent.News

What's breaking now, across thousands of outlets.

Tuesday, 13 October 2026 Reading Room

Health & Medicine

Zydus, Formycon Get USFDA Review Acceptance For Keytruda Biosimilar FYB206

Mumbai: Zydus Lifesciences and Formycon AG jointly announced on Monday, 13 October 2026, that the US Food and Drug Administration (USFDA) has accepted for review the Biologics License Application (BLA) for FYB206. FYB206 is a proposed biosimilar to Keytruda (pembrolizumab). Regulatory Acceptance This acceptance marks the first publicly announced USFDA review of an application for a Keytruda…

freepressjournal.in ·

Zydus, Formycon Get USFDA Review Acceptance For Keytruda Biosimilar FYB206

We haven't written up this one. Free Press Journal has the full story — the link below goes straight to it.

Read the original at freepressjournal.in →

More in Health & Medicine

Africa: CJID, MEAG to Launch Health Discourse Monitoring Platform

[CJID] The Centre for Journalism Innovation and Development (CJID) will launch SautiHealth, a technology-enabled platform for monitoring, analysing, and summarising public statements by health sector…

  • CJID and MEAG launch SautiHealth platform for African health discourse monitoring.
  • AI-powered summarisation provides structured, searchable access to verified health statements.
  • Platform enables trend analysis, trend identification, and evidence-based policy conversations.

·allafrica.com

More from Tuesday 13 October →